Tous Actualités
Suivre
Abonner Solianis Monitoring AG

Solianis Monitoring AG

Solianis Monitoring AG participates in the pioneering EU-project REACTION for improved diabetes management

Zürich (ots)

Solianis Monitoring AG is an important project
partner in the development of REACTION, a professional service 
platform for doctors, caregivers and patients to improve the long 
term management of diabetes.
The objective of the project is to improve glucose control in 
insulin requiring patients with diabetes by combining continuous 
glucose monitoring with intelligent Information and Communication 
Technology. It is funded by the European Union under the Framework 7 
program with a total budget of E 11 Mio. The continuous glucose 
monitoring systems will connect various hospitals and advanced 
mathematical systems through a wireless network to assess patients' 
conditions and provide therapy recommendations. These integrated 
services aim to assist healthcare professionals, non-professional 
caretakers  and patients in successful disease management  in order 
to improve the long term outcome for patients with diabetes. Solianis
will support the platform with its know-how  and its non- invasive 
continous glucose monitoring system. "We are very excited to engage 
in this project," says Mario Stark, CEO of Solianis. "This 
cooperation gives us the opportunity not only to leverage the 
advanced communication capabilities of our innovative system but also
to get closer to our main goal of improving the quality of life of 
patients with diabetes."
Solianis Monitoring AG is a Swiss medical device company 
developing an innovative non-invasive continuous glucose monitoring 
system for people with diabetes, their relatives and health care 
professionals. Its unique and proprietary technology is integrated in
a Multisensor Glucose Monitoring System which continuously delivers 
information on glucose variations.
REACTION stands for "Remote Accessibility to Diabetes Management 
and Therapy in Operational Healthcare Networks" and is a 4-years 
research project funded by the European Commission as part of the 7th
Framework Program on Personal Health Systems. Read more about the 
project on www.reactionproject.eu .

Contact:

Media:
Micaela Wochner
Phone: +41/44/306'80'29
Mobile: +41/79/431'79'34
E-Mail: Micaela.wochner@solianis.com
Internet: www.solianis.com

Investors:
Mario Stark
Phone: +41/44/306'80'40
Mobile: +41/79/542'88'74
E-Mail: Mario.stark@solianis.com

Plus de actualités: Solianis Monitoring AG
Plus de actualités: Solianis Monitoring AG
  • 08.02.2010 – 08:47

    Solianis Monitoring AG on its Way to Success - Market Entry as Planned in 2011

    Zurich (ots) - Solianis Monitoring AG presents its Non-Invasive, Continuous Glucose Monitoring System at the 3rd International Conference on Advanced Technologies and Treatments for Diabetes (Basel, Switzerland, February 10-13, 2010). Dr. Andreas Caduff, PhD, Chief Technology Officer of Solianis, will present the concept of Solianis' proprietary ...

  • 26.02.2009 – 11:07

    Scientific Recognition for Solianis based on Successful Tests

    Zurich, Swizerland (ots) - Recently, Solianis successfully finalized a series of tests during which patients with diabetes have worn its multisensor device for non-invasive glucose monitoring at home and at work in the office. The results of these real-life tests as well as earlier tests in a more controlled environment have encouraged Solianis to set up the final device and prepare the market introduction for 2010. ...